What is CS Bio?
Headquartered in Silicon Valley, CS Bio has operated as a premier provider of peptide synthesis instrumentation since 1993. The company maintains a robust market presence by delivering sophisticated, automated synthesis solutions that cater to a diverse clientele, ranging from academic research laboratories to large-scale commercial pharmaceutical manufacturers. With a footprint spanning over 30 countries, CS Bio distinguishes itself through the delivery of custom-engineered systems designed to meet the rigorous demands of modern biotechnology. Their portfolio, which encompasses both research-grade and industrial-scale equipment, serves as a critical infrastructure component for organizations engaged in complex molecular research and drug development.
How much funding has CS Bio raised?
CS Bio has raised a total of $2.5M across 2 funding rounds:
Debt
$1M
Debt
$1.5M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.5M led by PPP
Key Investors in CS Bio
PPP
Public-Private Partnership
What's next for CS Bio?
With the recent influx of capital, CS Bio is well-positioned to accelerate its research and development initiatives, focusing on the next generation of automated synthesis technology. The company's strategic roadmap likely involves scaling its manufacturing capabilities to meet the rising global demand for high-throughput peptide production. As the biotech sector continues to prioritize efficiency and precision, CS Bio's commitment to innovation will be pivotal in maintaining its competitive edge. Future growth will likely be driven by the expansion of its custom-built synthesizer offerings and the deepening of its integration within the global pharmaceutical research ecosystem, ensuring that the firm remains at the forefront of synthetic chemistry instrumentation.
See full CS Bio company page
